Literature DB >> 19297659

Differential IL-23 requirement for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar Enteritidis.

Sabine Siegemund1, Nicole Schütze, Silke Schulz, Kerstin Wolk, Katarzyna Nasilowska, Reinhard K Straubinger, Robert Sabat, Gottfried Alber.   

Abstract

Early activation of the IL-12/IFN-gamma axis has been shown following Salmonella enterica serovar Enteritidis (S. Enteritidis) infection. We were interested to study whether IL-22 and IL-17A production is initiated early in response to S. Enteritidis. We demonstrate here that IL-22 was strongly elevated in the peritoneal lavage fluid and in serum already 1 day post-intraperitoneal infection (d.p.i.) of mice; not only IL-22 but also IL-17A was produced ex vivo by activated peritoneal exudate cells (PEC). Peritoneal gammadelta T cells were identified as cellular source of IL-17A. The early IL-22 production was completely IL-23-dependent. In contrast, IL-17A production was only partially IL-23-dependent. To investigate the local production of upstream cytokines important for induction of IL-22, IL-17A and IFN-gamma during salmonellosis, the production of IL-23 and IL-12 was studied. Elevated p19 and p40 mRNA levels were found in PEC at 1 d.p.i., whereas p35 mRNA levels were not changed. Besides, the T(h)17-promoting cytokines IL-6, IL-1beta and transforming growth factor-beta were produced in response to S. Enteritidis. However, IL-6 was not required for IL-22 or IL-17A production by PEC. By ex vivo analysis of PEC at 1 d.p.i., we show that the major producers of early IL-12/23p40 in the peritoneal cavity were dendritic cells (DC), whereas macrophages notably contributed to IL-6 production. Taken together, these data suggest that DC initiate early IL-22 production at the site of infection which may contribute to resistance against salmonellosis. Furthermore, we provide evidence that production of IL-22 and IL-17A is differentially regulated during infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297659     DOI: 10.1093/intimm/dxp025

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  29 in total

1.  The nature of innate and adaptive interleukin-17A responses in sham or bacterial inoculation.

Authors:  Deborah L W Chong; Rebecca J Ingram; Daniel E Lowther; Roshell Muir; Shiranee Sriskandan; Daniel M Altmann
Journal:  Immunology       Date:  2012-07       Impact factor: 7.397

2.  Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells.

Authors:  Kristin J Ness-Schwickerath; Chenggang Jin; Craig T Morita
Journal:  J Immunol       Date:  2010-05-14       Impact factor: 5.422

3.  Early MyD88-dependent induction of interleukin-17A expression during Salmonella colitis.

Authors:  A Marijke Keestra; Ivan Godinez; Mariana N Xavier; Maria G Winter; Sebastian E Winter; Renée M Tsolis; Andreas J Bäumler
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

4.  Cytokine effects induced by the human autoallergen α-NAC.

Authors:  Susanne Hradetzky; Lennart M Roesner; Hari Balaji; Annice Heratizadeh; Irene Mittermann; Rudolf Valenta; Thomas Werfel
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

Review 5.  IL-17 in protective immunity to intracellular pathogens.

Authors:  Shabaana A Khader; Radha Gopal
Journal:  Virulence       Date:  2010 Sep-Oct       Impact factor: 5.882

6.  QseC mediates Salmonella enterica serovar typhimurium virulence in vitro and in vivo.

Authors:  Cristiano G Moreira; David Weinshenker; Vanessa Sperandio
Journal:  Infect Immun       Date:  2009-12-22       Impact factor: 3.441

Review 7.  Microbial-induced Th17: superhero or supervillain?

Authors:  Mandy J McGeachy; Stephen J McSorley
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

8.  IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections.

Authors:  Lorena Riol-Blanco; Vanja Lazarevic; Amit Awasthi; Meike Mitsdoerffer; Brian S Wilson; Andy Croxford; Ari Waisman; Vijay K Kuchroo; Laurie H Glimcher; Mohamed Oukka
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

9.  Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis.

Authors:  Nora Koutruba; Jason Emer; Mark Lebwohl
Journal:  Ther Clin Risk Manag       Date:  2010-04-15       Impact factor: 2.423

Review 10.  Colonization and effector functions of innate lymphoid cells in mucosal tissues.

Authors:  Myunghoo Kim; Chang H Kim
Journal:  Microbes Infect       Date:  2016-06-27       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.